Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Overview of attention for article published in EJNMMI Research, June 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

policy: 1 policy source

patent: 1 patent

Citations

dimensions_citation: 265 Dimensions

Readers on

mendeley: 172 Mendeley

Summary Policy documents Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy

Grant US-10688200-B2

United States of America